IP Library Granted Patent US 10,613,102
Granted Patent B2
US 10,613,102 · App. 15/119,291 · Granted Apr 7, 2020

Red blood cell detection

Inventors: Janine Scott Robb (Midlothian, GB); Andrew Gordon Robb (Midlothian, GB); David Cooper Robson (Midlothian, GB)
Assignee: QBD (QS-IP) Limited
G01N33/80G01N33/555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,613,102
App. No.
15/119,291
Granted
Apr 7, 2020
Kind
B2
Abstract

The present invention is based on the finding that red blood cell antigens can be exploited as a means to detect red blood cells/erythrocytes. Specifically, by identifying red blood cell antigens which are expressed by substantially all red blood cell types, it is possible to provide a method which achieves the reliable detection of red blood cells.

Claims (67)

1. A method of detecting red blood cells in a sample, said method comprising contacting the sample with binding agents capable of binding the red blood cell antigens control method for an assay, which assay requires the addition of red blood cells, said control method comprising:

detecting red blood cells with binding agents capable of binding red blood cells antigens listed as (i)-(iv) and that have a frequency of at least 99% in all red blood cell types:

(i) GPA;

(ii) GPB;

(iii) H; and

(iv) Rh29; and

confirming the presence of the red blood Cells in the assay and continuing the assay or confirming the absence of the red blood cells in the assay and discarding the assay or repeating the assay,

wherein detection of red blood cells bound to the binding agents confirms the presence of red blood cells in the sample.

2. The method of claim 1 , wherein the method is a control test to confirm the presence of red blood cells in a sample or process.

3. The method of claim 1 , wherein the sample is a sample of whole blood or a sample of adult, foetal, neonatal and/or antenatal plasma, serum or red blood cells prepared therefrom.

4. The method of claim 1 , wherein the sample is any volume or amount of a fluid or substance which comprises, potentially comprises or is suspected of comprising, red blood cells.

5. The method of claim 1 , wherein the method is a control test for an assay.

6. The method of claim 1 , wherein the binding agents are selected from the group consisting of:

(i) antibody or an antigen binding fragment thereof,

(ii) aptamers,

(iii) small molecule antibody mimetics,

(iv) nucleic acid ligands, and

(v) receptors from cells capable of binding the red blood cell antigens.

7. The method of claim 1 , wherein the binding agents are an antibody or an antigen binding fragment thereof.

8. The method of claim 1 , wherein the binding agents are an antibody, optionally a polyclonal or monoclonal antibody or antigen binding fragment of either.

9. The method of claim 1 , wherein the binding agents are immobilised, bound or adsorbed on to any suitable substrate.

10. The method of claim 1 , wherein the binding agents are immobilised, bound or adsorbed to all or part of a substrate.

11. The method of claim 1 , wherein the binding agents are immobilised, bound or adsorbed to one or more discrete, predetermined locations on a substrate.

12. The method of claim 11 , wherein the binding agents are immobilised as a plurality/series of distinct and/or discrete spots.

13. The method of claim 11 , wherein each discrete or predetermined location or spot on a substrate independently comprises the immobilised binding agents.

14. The method of claim 13 , wherein the binding agents are is immobilised, bound, and/or adsorbed to a substrate as an array or microarray.

15. The method of claim 1 , wherein the binding agents are immobilised to the substrate of an existing assay system.

16. The method of claim 15 , wherein, the existing assay system is a crossmatching or blood typing assay system.

17. The method of claim 9 , wherein the substrate is functionalised with one or more functional polymers selected from the group consisting of:

(i) glycidoxypropyltriethoxysilane;

(ii) poly-1-lysine;

(iii) aminopropylsilane;

(iv) carboyxsilane;

(v) hydrogels and polymer-brushes;

(vi) self-assembled monolayers; and

(vii) a silane based coating.

18. The method of claim 1 wherein the red blood cells are detected by means of autofluorescence.

19. A method, of confirming the presence of red blood cells in a sample used in an assay, said method comprising contacting the sample with one or more binding agents capable of binding red blood cells antigens (i)-(iv) that have a frequency of at least 99% in all red blood cell types selected from the group consisting of:

(i) GPA;

(ii) GPB;

(iii) H; and

(iv) Rh29;

wherein the detection of red blood cells bound to the binding agents confirms the presence of red blood cells in the sample and further wherein the assay is selected from the group consisting of:

(i) an immunological assay;

(ii) a crossmatching assay; and

(iii) a blood typing assay.

20. The method of claim 19 , wherein the method further comprises contacting the sample with binding agents capable of binding one or more red blood cell antigens selected from the group consisting of:

(i) En a ;

(ii) Ge:2;

(iii) Ge:3; and

(iv) Wr b .

21. A control test for an assay, said test comprising monoclonal antibodies capable of binding the red blood, cell antigens (i)-(iv) that have a frequency of at least 99% in all red blood cell types:

(i) GPA;

(ii) GPB;

(iii) H; and

(iv) Rh29.

22. The control test of claim 21 , wherein the test further comprises one or more binding agents capable of binding one or more of the red blood cell antigens selected from the group consisting of:

(I) En a ;

(ii) Ge:2;

(iii) Ge:3; and

(iv) Wr b .

23. The control test of claim 21 , wherein the control test is used as a positive control test to confirm the addition of red blood cells to a process, device, apparatus, assay and/or assay system.

24. The method of claim 1 , wherein the method further comprises contacting the sample with binding agents capable of binding one or more red blood cell antigens selected from the group consisting of:

(i) En a ;

(ii) Ge:2;

(iii) Ge:3; and

(iv) Wr b .

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Feb 17, 2023
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: QUOTIENT HOLDINGS FINANCE COMPANY LIMITED; ALBA BIOSCIENCE LIMITED; QBD (QS IP) LIMITED; QUOTIENT SUISSE SA
Reel/Frame 062735/0026 →
SECURITY INTEREST Recorded Feb 17, 2023
From: QUOTIENT HOLDINGS FINANCE COMPANY LIMITED; ALBA BIOSCIENCE LIMITED; QBD (QS IP) LIMITED; QUOTIENT SUISSE SA
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 062735/0051 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2016
From: ROBB, JANINE SCOTT; ROBB, ANDREW GORDON; ROBSON, DAVID COOPER
To: QBD (QS-IP) LIMITED
Reel/Frame 040088/0076 →
SECURITY INTEREST Recorded Oct 17, 2016
From: QUOTIENT LIMITED; ALBA BIOSCIENCE LIMITED; QBD (QS IP) LIMITED; QUOTIENT BIOCAMPUS LIMITED; QUOTIENT BIODIAGNOSTICS, INC.; QUOTIENT SUISSE SA
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 040035/0438 →
Priority Claims (1)
GB 1403115.7 · Feb 21, 2014 · national
Continuity (1)
Related Publication 20170059591A1 · Mar 2, 2017